HUTCHMED (China) (HCM) vs Zai Lab (ZLAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Zai Lab (ZLAB) has outperformed HUTCHMED (China) (HCM) over the past year, gaining 5.0% versus a loss of 5.6%. Over five years, HCM leads with a -62.4% price change compared with -72.7% for ZLAB. Zai Lab is the larger company by market cap ($2.63 billion vs $2.30 billion), about 1.1 times the size.
HUTCHMED (China) converts more of its revenue into profit, with a net margin of 83.3% versus -38.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCM | ZLAB |
|---|---|---|
| Share price | $13.22 | $21.03 |
| Market cap | $2.30B | $2.63B |
| 1-day change | -1.71% | -4.06% |
| YTD return | -0.83% | +19.22% |
| 1-year return | -5.57% | +5.04% |
| 5-year return | -62.42% | -72.67% |
| P/E ratio (TTM) | 132.20 | — |
| Forward P/E | 51.00 | — |
| EPS (TTM) | $0.10 | $-1.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $548.51M | $460.16M |
| Revenue growth (YoY) | -12.96% | +15.33% |
| Net income (latest FY) | $456.91M | $-175.54M |
| Gross margin | 38.68% | 58.60% |
| Operating margin | -7.14% | -49.86% |
| Net margin | 83.30% | -38.15% |
| 52-week high | $16.33 | $29.02 |
| 52-week low | $9.77 | $15.96 |
| Distance from 52-week high | -19.04% | -27.53% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +59.91% | +62.67% |
| Average volume | 64.48K | 991.34K |
| Shares outstanding | 173.81M | 124.84M |
| Employees | 1,790 | 1,784 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZLAB has outperformed HCM by 10.6 percentage points over the past year.
- HUTCHMED (China) is more profitable, keeping 83.3 cents of every revenue dollar as net income versus -38.1 cents for Zai Lab.
- Zai Lab grew revenue faster in its latest fiscal year (+15.33% vs -12.96%).
About HUTCHMED (China)
HCM stock →HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,790 employees
About Zai Lab
ZLAB stock →Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,784 employees
HCM vs ZLAB FAQ
Which is bigger, HUTCHMED (China) or Zai Lab?
Zai Lab (ZLAB) is larger, with a market capitalization of $2.63B compared with $2.30B for HUTCHMED (China) (HCM).
Which stock has performed better over the past year, HCM or ZLAB?
ZLAB returned +5.04% over the past 12 months, compared with -5.57% for HCM (price return, excluding dividends). Past performance does not predict future results.
Are HUTCHMED (China) and Zai Lab in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.